Rogdi was a novel gene with unknown function. According to GeneBank database, the gene is located on chromsome 10q12 and the length of coding regeion is 864 bp that encods 287 animo acids. Earlier studies in our laboratory showed that human ROGDI influenced rate of cell proliferaion in HeLa, Hep3B and NIH3T3 cells. In addition, we found Rogdi protien was up-regulated in fibrotic livers. Following various types of injury to liver, quiescent hepatic stellate cells (HSCs) transform to activated phenotype, leading to exprssion of £\-SMA, increasing rate of cell proliferation and depositing of extracellular matrix. In this study, we found that Rogdi protein was up-regulated in activated HSCs isolated and cultured from rat livers. By either overexpression or RNA interference of Rogdi, we found that Rogdi affected rate of HSCs proliferation, and expressions of £\-SMA and collagen type I. Expression of Rogdi protein was induced after PDGF treatment of rat HSCs. Additionally, we found that Rogdi was involved in MAPK and PI3K/Akt pathways. Furthermore, using wound healing assay and migration assay, Rogdi was found to regulate migration of activated HSCs.

Indiana University-Purdue University Indianapolis (IUPUI) / Liver fibrosis is a common consequence of various chronic liver diseases. Although transforming growth factor β 1 (TGFβ1) expression is known to be associated with liver fibrosis, the reduced clinical efficacy of TGFβ1 inhibition or the inefficiency to completely prevent liver fibrosis in mice with liver-specific knockout of TGF receptor II suggests that other factors can mediate liver fibrogenesis. As a TGFβ superfamily ligand, activin A signaling modulates liver injury by prohibiting hepatocyte proliferation, mediating hepatocyte apoptosis, promoting Kupffer cell activation, and inducing hepatic stellate cell (HSC) activation in vitro. However, the mechanism of action and in vivo functional significance of activin A in liver fibrosis models remain uncertain. Moreover, whether activin B, another ligand structurally related to activin A, is involved in liver fibrogenesis is not yet known. This study aimed to investigate the role of activin A and B in liver fibrosis initiation and progression. The levels of hepatic and circulating activin B and A were analyzed in patients with various chronic liver diseases, including end-stage liver diseases (ESLD), non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD). In addition, their levels were measured in mouse carbon tetrachloride (CCl4), bile duct ligation (BDL), and ALD liver injury models. Mouse primary hepatocytes, RAW264.7 cells, and LX-2 cells were used as in vitro models of hepatocytes, macrophages, and HSCs, respectively. The specificity and potency of anti-activin B monoclonal antibody (mAb) and anti-activin A mAb were evaluated using Smad2/3 luciferase assay. Activin A, activin B, or their combination were immunologically inactivated by the neutralizing mAbs in mice with progressive or established liver fibrosis induced by CCl4 or with developing cholestatic liver fibrosis induced by BDL surgery. In patients with ESLD, NASH, and ALD, increases in hepatic and circulating activin B, but not activin A, were associated with liver fibrosis, irrespective of etiology. In mice with CCl4-, BDL-, or alcohol-induced liver injury, activin B was persistently elevated in the liver and circulation, whereas activin A showed only transient increases. Activin B was expressed and secreted mainly by the hepatocytes and other cells, including cholangiocytes, activated HSCs, and immune cells. Exogenous administration of activin B promoted hepatocyte injury, activated macrophages to release cytokines, and induced a pro-fibrotic expression profile and septa formation in HSCs. Co-treatment of activin A and B interdependently activated the chemokine (C-X-C motif) ligand 1 (CXCL1)/inducible nitric oxide synthase (iNOS) pathway in macrophages and additively upregulated connective tissue growth factor expression in HSCs. Activin B and A had redundant, unique, and interactive effects on the transcripts related to HSC activation. The neutralization of activin B attenuated the development of liver fibrosis and improved liver function in mice with CCl4- or BDL-induced liver fibrosis and largely reversed the already established liver fibrosis in the CCl4 mouse model. These effects were improved by the administration of additional anti-activin A antibody. Combination of both antibodies also inhibited hepatic and circulating inflammatory cytokine production in the BDL mouse model. In conclusion, activin B is a potential circulating biomarker and potent promotor of liver fibrosis. Its levels in the liver and circulation increase significantly in both acute and chronic states of liver injury. Activin B might additively or interdependently cooperate with activin A, which directly acts on multiple liver cell populations during liver injury and fibrosis, as the combination of both proteins increases pro-inflammatory and pro-fibrotic responses in vitro. In addition, the neutralization of both activin A and activin B in vivo enhances the preventive and reversible effects of liver injury and fibrosis compared to that when activin B alone is neutralized. Our data reveal a novel target of liver fibrosis and the mechanism of activin B-mediated initiation of this process by damaging hepatocytes and activating macrophages and HSCs. Our findings show that activin B promotes hepatic fibrogenesis, and that targeting of activin B has anti-inflammatory and anti-fibrotic effects, which ameliorate liver injury by preventing or regressing liver fibrosis. Antagonizing either activin B alone or in combination with activin A prevents and regresses liver fibrosis in multiple animal studies, paving way for future clinical studies.

Abstract: Suppressor of cytokine signaling 1 (SOCS1) is an indispensable regulator of IFN-γ signaling and has been implicated in the regulation of liver fibrosis. However, it is not known whether SOCS1 mediates its anti-fibrotic functions in the liver directly, or via modulating IFN-γ, which has been implicated in attenuating hepatic fibrosis. Additionally, it is possible that SOCS1 controls liver fibrosis by regulating hepatic stellate cells (HSC), a key player in fibrogenic response. While the activation pathways of HSCs have been well characterized, the regulatory mechanisms are not yet clear. The goals of this study were to dissociate IFN-γ-dependent and SOCS1-mediated regulation of hepatic fibrogenic response, and to elucidate the regulatory functions of SOCS1 in H SC activation. Liver fibrosis was induced in Socs1[superscript -/-]Ifng[superscript -/-] mice with dimethylnitrosamine or carbon tetrachloride. Ifng[superscript -/-] and C57BL/6 mice served as controls. Following fibrogenic treatments, Socs1[superscript -/-]Ifng[superscript -/-] mice showed elevated serum ALT levels and increased liver fibrosis com-pared to mice Ifng[superscript -/-]. The latter group showed higher alanine aminotransferase (ALT) levels and fibrosis than C57BL/6 controls. The livers of Socs1-deficient mice showed bridging fibrosis, which was associated with increased accumulation of myofibroblasts and abundant collagen deposition. Socs1-deficient livers showed increased expression of genes coding for smooth muscle actin, collagen, and enzymes involved in remodeling the extracellular matrix, namely matrix metalloproteinases and tissue inhibitor of metalloproteinases. Primary HSCs from Socs1-deficient mice showed increased proliferation in response to growth factors such as HGF, EGF and PDGF, and the fibrotic livers of Socs1-deficient mice showed increased expression of the Pdgfb gene. Taken together, these data indicate that SOCS1 controls liver fibrosis independently of IFN-γ and that part of this regulation may occur via regulating HSC proliferation and limiting growth factor availability. / Résumé: Le suppresseur de la signalisation des cytokines 1 (SOCS1) est un régulateur indispensable de la signalisation de l'IFN-γ et a été aussi impliqué dans la régulation de la fibrose hépatique. Cependant, on ne sait pas si les fonctions anti-fibrotiques sont médiées directement dans le foie par SOCS1 ou par la modulation de l'IFN-γ, qui est connu pour son effet atténuateur de la fibrose hépatique. En outre, il est possible que SOCS1 contrôle la fibrose hépatique par la régulation des cellules stellaires hépatiques (CSH), un acteur clé dans la réponse fibrogénique. Alors que les voies d'activation des CSH ont été bien caractérisées, les mécanismes de régulation ne sont pas encore clairs. Les buts de cette étude étaient de dissocier la régulation de la réponse fibrogénique hépatique médiée par SOCS1 et celle dépendante de IFN-γ et d'élucider les fonctions régulatrices de SOCS1 dans l'activation des CSH. La fibrose hépatique a été induite chez des souris Socs1[indice supérieur -/-]Ifng[indice supérieur -/-] par la diméthylnitrosamine ou le tétrachlorure de carbone. Les souris Ifng[indice supérieur -/-] et C57BL6 ont servi comme contrôles. Après les traitements fibrogéniques, les souris Socs1[indice supérieur -/-]Ifng[indice supérieur -/-] ont montré des niveaux sériques élevés d'alanine aminotransférase (ALT) ainsi que l'augmentation de la fibrose du foie par rapport à des souris Ifng[indice supérieur -/-]. Le dernier groupe a montré des niveaux plus élevés d'ALT et de fibrose par rapport aux souris C57BL6 contrôles. Les foies des souris déficientes en Socs1 ont montré une fibrose septale, qui a été associée à une augmentation de l'accumulation des myofibroblastes et à un dépôt abondant du collagène. Les foies déficients en SOCS1 ont montré une expression accrue de gènes codant pour l'actine musculaire lisse, le collagène et les enzymes impliquées dans le remodelage de la matrice extracellulaire, à savoir les métalloprotéinases de la matrice et l'inhibiteur tissulaire des métalloprotéinases. Les CSH primaires de souris déficientes en Socs1 ont montré une prolifération accrue en réponse à des facteurs de croissance tels que le HGF, EGF et le PDGF. Aussi, les foies fibrotiques de souris déficientes en Socs1 ont montré une expression élevée du gène PDGFB. Pris ensemble, ces données indiquent que SOCS1 contrôle la fibrose hépatique indépendamment de l'IFN-γ et qu'une partie de cette régulation peut se produire en régulant la prolifération des HSC et en limitant la disponibilité des facteurs de croissance.

<p>Activin B, a TGFβ ligand, is associated with liver inflammatory response. We aimed to investigate whether it modulates liver fibrogenesis. <b> </b>Liver and serum activin B, along with its analog activin A, were analyzed in patients with liver fibrosis from different etiologies and in mouse acute liver injury and liver fibrosis models. Activin B, activin A, or both was immunologically neutralized in progressive or established carbon tetrachloride-induced mouse liver fibrosis. The direct effects of activin B and A on hepatocytes, macrophages, and hepatic stellate cells (HSCs) were evaluated <i>in vitro</i>. In human patients, increased activin B is associated with liver fibrosis irrespective of the etiologies. In mice, activin B exhibited persistent elevation in liver and circulation following the onset of liver injury, whereas activin A displayed transient increases. Neutralizing activin B largely prevented and remarkably regressed liver fibrosis, which was augmented by co-neutralizing activin A in mice. Mechanistically, activin B promoted hepatocyte injury, activated macrophages to release cytokines, and induced a pro-fibrotic expression profile and septa formation in HSCs, which were magnified by activin A. Furthermore, activin B and A interdependently activated the CXCL1/iNOS pathway in macrophages and additively upregulated CTGF transcript in HSCs <i>in vitro</i>. Consistently, the expression of these genes was prohibited by neutralizing either one of these two ligands in injured livers. Activin B potently drives the initiation and progression of liver fibrogenesis. It additively or interdependently cooperates with activin A, directly acts on multiple liver cell populations, and induces liver fibrogenesis.<b> </b>Antagonizing activin B or both activins B and A prevents and regresses liver fibrosis in mouse CCl₄ model, inspiring the development of a novel therapy of chronic liver diseases.</p>

京都大学 / 新制・課程博士 / 博士(医学) / 甲第24197号 / 医博第4891号 / 新制||医||1060(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 平井 豊博, 教授 万代 昌紀, 教授 伊達 洋至 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DGAM

No description available.

Made available in DSpace on 2015-03-03T14:02:14Z (GMT). No. of bitstreams: 1 JussaraMCM_Tese.pdf: 1097860 bytes, checksum: 122136921e4dddbf8d0e434cbbbd3653 (MD5) Previous issue date: 2009-12-03 / The activation of hepatic stellate cells (HSC) is considered the most important event in hepatic fibrogenesis. The precise mechanism of this process is unknown in autoimmune hepatitis (AIH), and more evidence is needed on the evolution of fibrosis. The aim of this study was to assess these aspects in children with type 1 AIH. We analyzed 16 liver biopsy samples from eight patients, paired before treatment and after clinical remission, performed an immunohistochemical study with anti-actin smooth muscle antibody and graded fibrosisand inflammation on a scale of 0:4 (Batts and Ludwig scoring system). We observedthere was no significant reduction in fibrosis scores after 24? 18 months (2.5 ? 0.93 vs. 2.0? 0.53, P = 0.2012). There was an important decrease in inflammation: portal (2.6 ?0.74 vs. 1.3? 0.89, P = 0.0277), periportal/periseptal (3.0 ?0.76 vs. 1.4 ? 1.06, P = 0.0277), and lobular (2.8 ? 1.04 vs. 0.9? 0.99, P =0.0179). Anti-actin smooth muscle antibodies were expressed in the HSC of the initial biopsies (3491.93 ?2051.48 lm2), showing a significant reduction after remission (377.91 ?439.47 lm2) (P = 0.0117). HSC activation was demonstrated in the AIH of children. The reduction of this activation after clinical remission, which may precede a decrease in fibrosis, opens important perspectives in the follow-up of AIH. / A ativa??o das c?lulas hep?ticas estreladas (CHE) ? considerada o evento mais importante na fibrog?nese hep?tica. Na hepatite autoimune (HAI) este mecanismo ? desconhecido e maiores evid?ncias s?o necess?rias quanto ? evolu??o da fibrose. O objetivo desse estudo foi avaliar a ativa??o das CHE e a evolu??o da fibrose hep?tica em crian?as portadoras de HAI tipo 1. Foram analisadas 16 bi?psias hep?ticas pareadas de oito pacientes, antes do tratamento e ap?s a remiss?o cl?nica atrav?s de estudo imuno-histoqu?mico com anticorpo anti-??-actina de m?sculo liso e realizada a grada??o da fibrose e da inflama??o empregando-se o sistema de escores de Batts e Ludwig (0-4). N?o houve significante redu??o nos escores de fibrose ap?s intervalo de tempo de 24? 18 meses entre as bi?psias (2,5 ? 0,93 vs. 2,0? 0,53, P = 0,2012). Observou-se redu??o significante na inflama??o: portal (2,6?0,74 vs. 1,3? 0,89, P = 0,0277), periportal/perisseptal (3,0 ?0,76 vs. 1,4 ? 1,06, P =0,0277) e lobular (2,8 ? 1,04 vs. 0,9? 0,99, P =0,0179). A -actina de m?sculo liso nas CHE foi expressa em bi?psias hep?ticas iniciais (3491,93 ?2051,48 ?m2) e mostrou significante redu??o ap?s a remiss?o cl?nica (377,91 ?439,47 ?m2) (P = 0,0117). A ativa??o de CHE foi demonstrada em crian?as portadoras de HAI tipo 1. A redu??o de sua ativa??o ap?s remiss?o cl?nica, a qual pode preceder a redu??o da fibrose, abre importantes perspectivas no follow-up da HAI

A fibrose hepática resulta da cronicidade da injúria celular, ocasionando acúmulo dos componentes da matriz extracelular (MEC) pela ativação, principalmente, de células estreladas e fibroblastos portais em miofibroblastos. Estas células se conectam através de junções comunicantes do tipo gap, formadas por proteínas denominadas conexinas (Cx). As junções gap são responsáveis pelo fluxo de moléculas e íons entre as células, desempenhando importante função no controle da homeostasia tecidual. Diversos tipos de conexinas foram descritas nas células hepáticas. Os hepatócitos expressam Cx32 e Cx26, enquanto as demais células não-parenquimatosas expressam Cx43. Alguns estudos analisaram a expressão das conexinas e das junções gap em processos de reparação e fibrogênese em diferentes tecidos, no entanto, poucos avaliaram seu papel na fibrogênese hepática. Sendo assim, o objetivo deste estudo foi avaliar os aspectos morfológicos, histopatológicos e moleculares da fibrose hepática, induzida por tetracloreto de carbono (CCl4), em animais deficientes para as conexinas 43 (Cx43+/-) ou 32 (Cx32-/-). Foram analisados dados biométricos, histopatológicos, ultra-estruturais, imuno-histoquímicos e bioquímicos, além da expressão gênica e protéica das conexinas. Os aspectos moleculares da fibrose hepática foram analisados pela expressão de genes relacionados com a deposição e degradação da matriz extracelular por PCR em tempo real. As análises macroscópicas e de varredura demonstraram um processo de micronodulação da superfície hepática mais acentuado nos camundongos Cx43+/- fibróticos em relação aos animais wild-type (Cx43+/+) fibróticos. Adicionalmente, estes animais apresentaram maior proporção volumétrica de colágeno no tecido hepático; redução na atividade necroinflamatória tecidual; redução nas concentrações séricas de AST e ALT; redução na proliferação celular dos hepatócitos e redução na expressão dos genes: colágeno tipo I, TGF&beta;-1, MMP-2, MMP-13 e TIMP-1. Por sua vez, os camundongos Cx32-/- fibróticos apresentaram aumento na deposição de colágeno no parênquima hepático; aumento na atividade necroinflamatória tecidual e aumento nos níveis séricos das enzimas hepáticas AST, ALT e fosfatase alcalina em comparação aos animais wild-type (Cx32+/+) fibróticos. Também foram observadas redução na proliferação hepatocelular e maior quantidade de corpúsculos apoptóticos no tecido hepático. Baseando-se em todos os resultados obtidos, observou-se que ambos os modelos animais apresentaram aumento da fibrose hepática, aparentemente ocasionada por diferentes modos de ação. Os animais deficientes em Cx43 apresentaram menor capacidade de degradação do colágeno, ocasionando seu acúmulo no tecido hepático. Por outro lado, os animais deficientes em Cx32 apresentaram maior deposição de colágeno em resposta à injúria hepatocelular mais acentuada, aliada ao desequilíbrio entre as taxas de proliferação celular e apoptose. Em conclusão, os resultados obtidos neste trabalho demonstraram a importante participação das conexinas no controle da fibrogênese hepática, e que podem representar potenciais alvos terapêuticos para o tratamento das doenças hepáticas crônicas em humanos e animais. / Hepatic fibrosis results from chronic cell injury, leading to accumulation of components of extracellular matrix (ECM) through activation mainly of hepatic stellate cells and portal fibroblasts into myofibroblasts. These cells communicate through intercellular gap junctions composed of proteins known as connexins (Cx). Gap junctions are responsible for the exchange of molecules and ions among cells, playing an important role in the control of tissue homeostasis. Several subtypes of connexins were described among hepatic cells. Hepatocytes express Cx32 and Cx26, while the other non-parenchymal cells express Cx43. Some studies analyzed the expression of connexins and gap junctions on processes of healing and fibrogenesis in different tissues; however, few studies evaluated its role on hepatic fibrogenesis. Thus, the objective of this study was to evaluate morphological, histopathological and molecular aspects of hepatic fibrosis induced by carbon tetrachloride (CCl4) in animals with connexin 43 (Cx43+/-) or 32 (Cx32-/-) deficiency. We analyzed biometric, histopathological, ultrastructural, immunohistochemical and biochemical data, besides gene and protein expression of connexins. Molecular aspects of hepatic fibrosis were analyzed with the expression of genes related to deposition and degradation of extracellular matrix by real time PCR. Macroscopic and Scanning Electron Microscopy analyses showed a process of micronodulation of hepatic surface more accentuated on Cx43+/- fibrotic mice when compared to fibrotic wild-type (Cx43+/+) animals. Additionally, these animals presented a higher collagen volumetric proportion on hepatic tissue; reduction of tissue necroinflammatory activity; reduction of serum AST and ALT; reduction of hepatocytes proliferation and reduction of expression type I collagen, TGF&beta;-1, MMP-2, MMP-13 and TIMP-1 genes. Fibrotic Cx32-/- mice presented an increase of collagen deposition in hepatic parenchyma; increase of tissue necro-inflammatory activity and increase of liver enzymes AST, ALT and alkaline phosphatase when compared to fibrotic wild-type (Cx32+/+) animals. Reduction of hepatocellular proliferation and a higher amount of apoptotic bodies on hepatic tissue were also observed. Based on the results obtained, we observed that both animal models showed an increase of hepatic fibrosis, apparently caused by different modes of action. Cx43 deficient animals showed a reduced capacity to degrade collagen, causing its accumulation in the hepatic tissue. Cx32 deficient animals showed an increased collagen deposition in response to accentuated hepatocellular injury, together to an unbalance between rates of cellular proliferation and apoptosis. In conclusion, results obtained on this study demonstrate an important role of connexins on the control of hepatic fibrogenesis, which could represent potential therapeutical targets for the treatment of chronic liver diseases in humans and animals.

A fibrose hepática resulta da cronicidade da injúria celular, ocasionando acúmulo dos componentes da matriz extracelular (MEC) pela ativação, principalmente, de células estreladas e fibroblastos portais em miofibroblastos. Estas células se conectam através de junções comunicantes do tipo gap, formadas por proteínas denominadas conexinas (Cx). As junções gap são responsáveis pelo fluxo de moléculas e íons entre as células, desempenhando importante função no controle da homeostasia tecidual. Diversos tipos de conexinas foram descritas nas células hepáticas. Os hepatócitos expressam Cx32 e Cx26, enquanto as demais células não-parenquimatosas expressam Cx43. Alguns estudos analisaram a expressão das conexinas e das junções gap em processos de reparação e fibrogênese em diferentes tecidos, no entanto, poucos avaliaram seu papel na fibrogênese hepática. Sendo assim, o objetivo deste estudo foi avaliar os aspectos morfológicos, histopatológicos e moleculares da fibrose hepática, induzida por tetracloreto de carbono (CCl4), em animais deficientes para as conexinas 43 (Cx43+/-) ou 32 (Cx32-/-). Foram analisados dados biométricos, histopatológicos, ultra-estruturais, imuno-histoquímicos e bioquímicos, além da expressão gênica e protéica das conexinas. Os aspectos moleculares da fibrose hepática foram analisados pela expressão de genes relacionados com a deposição e degradação da matriz extracelular por PCR em tempo real. As análises macroscópicas e de varredura demonstraram um processo de micronodulação da superfície hepática mais acentuado nos camundongos Cx43+/- fibróticos em relação aos animais wild-type (Cx43+/+) fibróticos. Adicionalmente, estes animais apresentaram maior proporção volumétrica de colágeno no tecido hepático; redução na atividade necroinflamatória tecidual; redução nas concentrações séricas de AST e ALT; redução na proliferação celular dos hepatócitos e redução na expressão dos genes: colágeno tipo I, TGF&beta;-1, MMP-2, MMP-13 e TIMP-1. Por sua vez, os camundongos Cx32-/- fibróticos apresentaram aumento na deposição de colágeno no parênquima hepático; aumento na atividade necroinflamatória tecidual e aumento nos níveis séricos das enzimas hepáticas AST, ALT e fosfatase alcalina em comparação aos animais wild-type (Cx32+/+) fibróticos. Também foram observadas redução na proliferação hepatocelular e maior quantidade de corpúsculos apoptóticos no tecido hepático. Baseando-se em todos os resultados obtidos, observou-se que ambos os modelos animais apresentaram aumento da fibrose hepática, aparentemente ocasionada por diferentes modos de ação. Os animais deficientes em Cx43 apresentaram menor capacidade de degradação do colágeno, ocasionando seu acúmulo no tecido hepático. Por outro lado, os animais deficientes em Cx32 apresentaram maior deposição de colágeno em resposta à injúria hepatocelular mais acentuada, aliada ao desequilíbrio entre as taxas de proliferação celular e apoptose. Em conclusão, os resultados obtidos neste trabalho demonstraram a importante participação das conexinas no controle da fibrogênese hepática, e que podem representar potenciais alvos terapêuticos para o tratamento das doenças hepáticas crônicas em humanos e animais. / Hepatic fibrosis results from chronic cell injury, leading to accumulation of components of extracellular matrix (ECM) through activation mainly of hepatic stellate cells and portal fibroblasts into myofibroblasts. These cells communicate through intercellular gap junctions composed of proteins known as connexins (Cx). Gap junctions are responsible for the exchange of molecules and ions among cells, playing an important role in the control of tissue homeostasis. Several subtypes of connexins were described among hepatic cells. Hepatocytes express Cx32 and Cx26, while the other non-parenchymal cells express Cx43. Some studies analyzed the expression of connexins and gap junctions on processes of healing and fibrogenesis in different tissues; however, few studies evaluated its role on hepatic fibrogenesis. Thus, the objective of this study was to evaluate morphological, histopathological and molecular aspects of hepatic fibrosis induced by carbon tetrachloride (CCl4) in animals with connexin 43 (Cx43+/-) or 32 (Cx32-/-) deficiency. We analyzed biometric, histopathological, ultrastructural, immunohistochemical and biochemical data, besides gene and protein expression of connexins. Molecular aspects of hepatic fibrosis were analyzed with the expression of genes related to deposition and degradation of extracellular matrix by real time PCR. Macroscopic and Scanning Electron Microscopy analyses showed a process of micronodulation of hepatic surface more accentuated on Cx43+/- fibrotic mice when compared to fibrotic wild-type (Cx43+/+) animals. Additionally, these animals presented a higher collagen volumetric proportion on hepatic tissue; reduction of tissue necroinflammatory activity; reduction of serum AST and ALT; reduction of hepatocytes proliferation and reduction of expression type I collagen, TGF&beta;-1, MMP-2, MMP-13 and TIMP-1 genes. Fibrotic Cx32-/- mice presented an increase of collagen deposition in hepatic parenchyma; increase of tissue necro-inflammatory activity and increase of liver enzymes AST, ALT and alkaline phosphatase when compared to fibrotic wild-type (Cx32+/+) animals. Reduction of hepatocellular proliferation and a higher amount of apoptotic bodies on hepatic tissue were also observed. Based on the results obtained, we observed that both animal models showed an increase of hepatic fibrosis, apparently caused by different modes of action. Cx43 deficient animals showed a reduced capacity to degrade collagen, causing its accumulation in the hepatic tissue. Cx32 deficient animals showed an increased collagen deposition in response to accentuated hepatocellular injury, together to an unbalance between rates of cellular proliferation and apoptosis. In conclusion, results obtained on this study demonstrate an important role of connexins on the control of hepatic fibrogenesis, which could represent potential therapeutical targets for the treatment of chronic liver diseases in humans and animals.

A fibrose hepática é uma patologia que acompanha outras doenças crônicas do fígado como a cirrose e o hepatocarcinoma. As células estreladas hepáticas (HSC, do inglês hepatic stellate cells) compõem uma população celular heterogênea que se caracteriza por transitar entre dois fenótipos. As células com fenótipo quiescente possuem a capacidade de armazenar vitamina A em gotas lipídicas. Os insultos ao fígado desencadeiam uma resposta inflamatória que gera estímulos parácrinos e autócrinos mediados por citocinas e espécies reativas. Neste contexto, as HSC assumem um fenótipo ativado fibrogênico e tornam-se responsáveis pela cicatrização hepática. Danos crônicos ao fígado levam a uma deposição de matriz extracelular exagerada que configura o estado patológico da fibrose. O resveratrol (RSV – 3,4’,5-tri-hidroxi-trans-estilbeno) é uma fitoalexina produzida por algumas espécies de plantas. Inúmeros efeitos benéficos à saúde são atribuídos ao RSV por causa do seu potencial antioxidante, antiinflamatório e pró-apoptótico. Estudos anteriores mostraram que tratamento da GRX, uma linhagem murina de HSC ativadas, com concentrações de RSV próximas as biodisponíveis (0,1 a 1 μM) resultou em parada do ciclo na fase S com consequente inibição de proliferação celular, um efeito associado à citotoxicidade e que pode favorecer a resolução da fibrose hepática. Neste estudo, por técnicas espectrofotométricas, foi demonstrado que tratamento da GRX por 24 horas com concentrações entre 0,1 a 50 μM de RSV promoveu um efeito pró-oxidante que causa uma citotoxicidade dependente da dose, bastante aumentada no grupo tratado com a concentração mais alta. Os efeitos citotóxicos atenuados encontrados nas células tratadas por 120 horas sugerem que a GRX pode se tornar resistente a estes efeitos. O potencial pró-oxidante do RSV foi o ponto de partida para investigar a possibilidade de que esta fitoalexina provocasse uma alteração no metabolismo mitocondrial da GRX. Para isso, os efeitos do RSV (1 a 50 μM) na função mitocondrial, na indução de morte mediada por estas organelas e na autofagia/mitofagia foram investigados por técnicas de espectrofotometria, de imunocitoquímica, de citometria de fluxo, de microscopia confocal e de microscopia eletrônica de transmissão em GRX tratadas por 24 e 120 horas. Foi demonstrado que todas as concentrações de RSV promovem apoptose por meio da ativação de caspases, alteram a dinâmica/função mitocondrial e induzem o aumento de autofagia/mitofagia na GRX. No entanto, o RSV provocou biogênese de mitocôndrias nos grupos tratados com 1 e 10 μM, enquanto que o tratamento com 50 μM causou dano celular evidente na GRX, sem induzir biogênese de mitocôndrias. Desta forma, é possível que a citotoxicidade “dose-dependente” do RSV, que causa a morte celular e dano oxidativo em 24 horas de tratamento, esteja relacionada com o desequilíbrio entre a indução concomitante de apoptose mediada por dano mitocondrial, autofagia/mitofagia e biogênese de mitocôndrias. Por fim, foi investigada a liberação de TNF-α, Interleucina-6 e Interleucina-10 pela GRX tratada por 24 e 120 horas com RSV (0,1 a 50 μM), considerando o papel antiinflamatório do RSV e o papel das HSC ativadas na sinalização autócrina que contribui para a modulação fenotípica destas células. Foi demonstrado que o tratamento da GRX com RSV por 24 e 120 horas induziu a redução da liberação de Interleucina-6; enquanto que a liberação de TNF-α e Interleucina-10 foi aumentada. Estes resultados confirmam um efeito antiinflamatório do RSV que deve contribuir na prevenção da ativação ou da perpetuação do estado ativado das HSC por meio de sinalização autócrina. Ainda que a concentração do RSV seja importante para efetivamente induzir a morte das HSC ativadas, o tratamento com esta fitoalexina pode ser promissor para a resolução da fibrose hepática por diminuir a população de células ativadas e, possivelmente, prevenir a perpetuação do estado fenotípico ativado. Estudos avaliando indicadores de quiescência em células tratadas são ainda necessários para desvendar completamente os efeitos do RSV quanto às possibilidades de inibição da perpetuação ou reversão fenotípica das HSC ativadas. / Liver fibrosis is a disease that accompanies other hepatic chronic diseases such as cirrhosis and hepatocellular carcinoma. Hepatic stellate cells (HSC) are a heterogeneous cell population characterized by transiting between two phenotypes. Cells with a quiescent phenotype are able to store vitamin A into lipid droplets. Damage to the liver trigger an inflammatory response that generates paracrine and autocrine stimulation mediated by cytokines and reactive species. In this context, HSC assume an activated and fibrogenic phenotype responsive for hepatic wound-healing. Chronic insults to the liver lead to an excessive deposition of extracellular matrix that configures the pathological state of fibrosis. Resveratrol (RSV – 3,4’,5-tri-hidroxi-trans-stilbeno) is a phytoalexin produced by some species of plants. Several beneficial effects are attributed to this molecule due to its antioxidant, antiproliferative and pro-apoptotic potential. Previous studies showed that treatment with bioavailable concentrations of RSV (0.1 to 1 μM) promoted an arrest cycle at the S phase in GRX, a murine activated HSC model, leading to cell proliferation inhibition, a cytotoxic effect that contributes to the liver fibrosis resolution. In this study, it was shown by spectrophotometric techniques that GRX treatment for 24 hours at concentrations between 0.1 to 50 μM of RSV promoted a fairly clear pro-oxidant effect that causes a dose-dependent cytotoxicity that was higher in the group treated with 50 μM. The attenuated cytotoxicity found after 120 hours of GRX treatment suggest that these cells became resistant to this effect. The pro-oxidant potential of RSV was the starting point for investigating the possibility that this phytoalexin would cause a change in the GRX mitochondrial metabolism. Thus, the effects of RSV (1 to 50 μM) on altering the mitochondrial function, on inducing mitochondrial-mediated cell death, and autophagy/mitofagia were investigated in GRX treated for 24 and 120 hours by spectrophotometric techniques, immunocytochemistry, flow cytometry, confocal microscopy, and transmission electron microscopy. All the RSV concentrations promote cell apoptosis through caspases activation, alter the mitochondrial dynamics and function, and induce an increase of autophagy/mitofagia. Curiously, only 1 and 10 μM of RSV induced mitochondrial biogenesis in GRX, while the highest concentration caused an evident cell damage without inducing mitochondrial biogenesis. Thus, it is possible that the "dose-dependent" cytotoxicity of RSV, which causes cell death and oxidative damage in 24 hours of treatment, is related to an imbalance between the concomitant induction of mitochondrial-mediated apoptosis, autophagy/mitofagia, and mitochondrial biogenesis. Finally, it was investigated the release of TNF-α, Interleukin-6 and Interleukin-10 by GRX treated for 24 and 120 hours with RSV (0.1 to 50 μM), considering the anti-inflammatory role of RSV and the autocrine signalling role of HSC that contributes to the perpetuation of its activated phenotype. It was demonstrated that GRX treatment with RSV for 24 and 120 hours reduced the release of Interleukin-6 in the culture medium; whereas the release of TNF-α and Interleukin-10 was increased. These results confirm the anti-inflammatory properties of RSV and may contribute to the prevention of HSC activation through autocrine signalling. Although RSV concentration is important to effectively induce activated HSC death, cells treatment with this phytoalexin may be promising for liver fibrosis resolution through decreasing the population of activated cells or through preventing the perpetuation of activated state of HSC. Future studies evaluating the quiescence indicators of GRX under RSV treatment are still needed to fully unravel the effects of this phytoalexin on inhibiting the perpetuation of activated HSC or reversing its activated phenotype.